Rieger Jayson 4

What Happened

• Jayson Rieger, CEO, President and a director of Verrica Pharmaceuticals (VRCA), was granted a derivative award on June 5, 2026 covering 512,269 shares. The filing reports the acquisition price as $0.00 (the grant of an option/award), so no cash was exchanged on grant.
• The grant was approved by a board committee on December 23, 2025 and became effective after shareholders approved an amendment to the company's equity plan on June 5, 2026.

Key Details

• Transaction date: 2026-06-05; Report filed: 2026-06-09.
• Instrument: Option/award (derivative) for 512,269 shares; reported value at grant: $0.00.
• Vesting: 50% vests when the Nasdaq closing price ≥ $15.00; remaining 50% vests when the Nasdaq closing price ≥ $25.00. Vesting in each case is also conditioned on Rieger's continuous service through each vesting date.
• Shares owned after the transaction: not provided in the supplied filing excerpt.
• Notes: Grant was conditional on shareholder approval of an amendment to the 2018 Equity Incentive Plan (approved June 5, 2026).

Context

• This was an equity award (option-style derivative) rather than an open-market buy or sale — it does not represent an immediate purchase of shares or realization of cash. Vesting is tied to future stock-price performance and continued service, so these options may not convert into owned shares unless those conditions are met.